ITMCTR2200006560
Not yet recruiting
Phase 4
Clinical observation on the efficacy, safety and pharmacoeconomics of Guben Kechuan granule in treating chronic bronchitis
CHINA-JAPAN FRIENDSHIP HOSPITA0 sitesTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHINA-JAPAN FRIENDSHIP HOSPITA
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Consistent with the diagnosis of chronic bronchitis;
- •(2\) The scores of main symptoms of chronic bronchitis (cough, expectoration and wheezing) were all \= 1 point;
- •(3\) Age 18\-75 years old (including 18 and 75 years old), gender is not limited;
- •(4\) Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.
Exclusion Criteria
- •(1\) Acute bronchitis or acute exacerbation of chronic bronchitis in recent 1 month;
- •(2\) Pulmonary tuberculosis, eosinophilic bronchitis, bronchial lung cancer, idiopathic pulmonary fibrosis, pneumonia, bronchial asthma, bronchiectasis, gastroesophageal reflux and other diseases with cough, expectoration or wheezing symptoms;
- •(3\) Have taken drugs similar to the functional indications of the test drug in the past 2 weeks;
- •(4\) SCR of renal function is greater than the upper limit of reference value or ALT and AST of liver function are more than 2 times of the upper limit of reference value;
- •(5\) Complicated with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney, digestive and hematopoietic system;
- •(6\) Have a long history of alcohol and drug abuse;
- •(7\) Pregnant and lactating women and during the trial cannot be strictly contraception;
- •(8\) Have a history of allergy to test drug components;
- •(9\) Having intellectual disability or mental disorder;
- •(10\) Participated in other clinical trials in the past 3 months;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Clinical Evaluation of the AqueSys Implant for the Treatment of ocular hypertension and open angle glaucomaOcular hypertension and open angle glaucomaEye - Diseases / disorders of the eyeACTRN12610000021077Aquesys Inc20
Recruiting
Phase 2
Clinical evaluation of the safety and effectiveness Oral capsules in the prevention and treatment of hair lossIRCT20190210042676N18Knowledge-based company of Janus20
Recruiting
Phase 2
Clinical evaluation of the safety and effectiveness of the nanofiber undereye pad to improve surface wrinkles and dark circles under the eyesIRCT20210130050179N9ano tarpak company10
Active, not recruiting
Phase 1
Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)on resectable Hepatocellular carcinoma (HCC)MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511538-11-00Institut Gustave Roussy40
Withdrawn
Not Applicable
Clinical investigation of the safety and efficacy of ALIMAXX-B biliary stent for bile duct obstructioCBD obstructionmalignant biliary obstruction10018008NL-OMON31943Alveolus, Inc.10